摘要
重组人血管内皮抑素(rh-endostatin,商品名:恩度)是一种广谱的抗血管生成分子靶向药物,主要通过抑制血管内皮细胞增值和迁移来抑制肿瘤生长。近年来,恩度用于治疗女性恶性肿瘤的研究逐渐增多,并取得了较好的疗效,且毒副作用小。本文就近年恩度在女性恶性肿瘤治疗中的应用研究进展进行综述。
Recombinant human endostatin(Endostar),a broad spectrum drug targeting angiogenesis,can inhibit tumor growth by suppressing the proliferation and migration of vascular endothelial cells.In recent years,there is a gradual increase in the treatment of female malignant tumors with Endostar,which produces good efficacy and little toxicity.This paper reviews the recent progress in clinical application of Endostar in the treatment of female malignant tumors.
作者
赖军明
林红
罗辉
胡爽
LAI Junming;LIN Hong;LUO Hui;HU Shuang(2015 Grade of Medical Department of Graduate School Nanchang University,Nanchang 330006,China;Department of Oncology of the First Affiliated Hospital,Nanchang University,Nanchang 330006,China;Department of Oncology of the 171 st Hospital of Chinese Peole’s Libration Army,Jiujiang 332000,China)
出处
《实用临床医学（江西）》
CAS
2017年第11期104-107,共4页
Practical Clinical Medicine
关键词
重组人血管内皮抑素
恩度
乳腺癌
宫颈癌
卵巢癌
临床应用
recombinant human endostatin
endostatar
breast carcinoma
cervical carcinoma
ovarian carcinoma
clinical application
